By Mukundan Sivaraj · AIM Media House
Thermo Fisher Scientific, a Waltham, Massachusetts-based life sciences instrument and equipment maker, reported second-quarter 2026 adjusted earnings of $6.03 per share on revenue of $11.99 billion, beating analyst estimates of $5.72 per share and $11.71 billion in sales. Shares rose 8.97% in early trading.
The company raised its full-year guidance, pointing to broad-based demand that included its newest AI-enabled instruments and software. Marc Casper, Chairman and CEO of Thermo Fisher Scientific, says customer activity strengthened across every end market the company serves.
"Customer activity across our end markets continued to strengthen," Casper says. Pharma and biotech, the company's largest end market at about 60% of revenue, delivered mid-single-digit growth for the quarter.
AI Tools Headline a Wave of Product Launches Casper credited the quarter's growth to new products rather than market conditions alone. "Innovation is the most important driver," Casper says.
At the American Society for Mass Spectrometry conference in June, the company launched its Orbitrap Tribrid Apex and Orbitrap Excedion mass spectrometers, both built with AI-driven capabilities aimed at drug development research.
The company also expanded its suite of AI-powered software, which it says delivers smarter lab workflows and speeds up proteomics research. Casper says Thermo Fisher is deploying AI across its own operations too, using it to accelerate its internal PPI Business System.
That system spans manufacturing and productivity efforts across the company. Pharma's AI Spending Is Filling Thermo Fisher's Order Book The demand for Thermo Fisher's tools is tied to a broader wave of pharmaceutical investment in AI-based drug discovery.
Casper says his conversations with pharma executives increasingly center on artificial intelligence.
Continue on AIM Media House